Objective: To evaluate the effect of the use of the hemoglobinometer in primary care on the clinical results of patients with chronic anemia.

Methods: The ANHEMOG study is a randomized controlled trial with two parallel arms, intervention and control. It was approved at december 11, 2017. The study randomizes 138 patients with chronic anemia. In the intervention arm, a monthly capillary hemoglobin measurement will be performed with a hemoglobinometer. If a decrease in hemoglobin concentration is detected, an existing transfusion circuit will be followed. Social, demographic and quality of life variables will be collected from all participants.

Hypothesis:

The results of the research will have an impact on people with chronic anemia who would receive red blood cell transfusion when needed without delay. The improvement in the times of action would reduce decompensations from chronic diseases, visits to the emergency room and hospital admissions, and therefore would improve the quality of life of these patients. Furthermore, the management of the different interventions by the Case Management Nurse (EGC), in this regard, improves the current fragmentation of the different levels of care.

Inclusion Criteria:

• People over 40 years old
• Had received 2 or more red blood cell transfusions due to chronic disease, during a year.
• The health provider in Primary Care is the Institut Català de la Salut.

Exclusion Criteria:

• Presenting kidney failure on hemodialysis treatment.
• Being in palliative care situation
• Presenting a moderate-severe cognitive impairment, with a Pfeiffer scale score higher than 5.
• Not having a caregiver able to detect signs of decompensation.

Study protocol will be sent to publication in the next months

Open access to read as soon as published

Open